Evercore ISI cuts Foghorn Therapeutics stock rating on trial failure

Evercore ISI cut Foghorn Therapeutics to In Line from Outperform and reduced its price target to $3 from $14 after the company and Eli Lilly discontinued lead program FHD-909, which failed to show sufficient efficacy, as well as a separate SMARCA2 degrader program. The article also reports a 40% workforce reduction, the end of the Eli Lilly collaboration, and multiple analyst downgrades or price-target cuts; Foghorn’s shares are down 64% year to date at $1.95. Evercore estimates about $131 million in net cash at year-end 2026 and retains $150 million of pipeline value, but says future programs are early-stage and require a longer wait.

Analysis

The key repricing is from a partnered clinical asset to a cash-and-optionality vehicle. Loss of the lead program weakens external validation for the platform; that can raise the discount investors apply to early-stage programs even if the workforce cuts lower near-term burn. The cuts are therefore a runway-positive but pipeline-capacity-negative signal, not an unambiguously bullish cost reset. Lilly’s exit matters more as lost validation and potential development support than as a material read-through to Lilly’s earnings.

The quoted year-end 2026 net-cash estimate is not a present-day floor: current cash, liabilities, restructuring costs, collaboration economics, and the pace of post-cut spending need verification. With the shares already sharply repriced, a fresh outright short risks being squeezed by cash optionality or a new partnership; a long requires evidence that remaining programs can produce decision-grade data before cash is depleted. Near term, analyst actions may add little information beyond the clinical failure. Over 1–3 months, watch for a detailed runway update and pipeline prioritization; over 6–18 months, clinical evidence—not cost cuts—must restore platform credibility. The bearish thesis is falsified by credible, independently assessable clinical progress or a funded partnership on attractive terms. A further cash-burn acceleration, financing, or additional program attrition would reinforce it.

Key Decisions for Investors

• Avoid initiating a directional FHTX position solely on the analyst target cuts or the apparent cash discount. First verify the latest cash balance, liabilities, restructuring charges, collaboration termination terms, and quarterly burn; the supplied future net-cash estimate is not a current valuation anchor.
• For existing longs, size as a high-risk, early-stage biotech option rather than a diversified pipeline story. Reassess if management’s next update does not specify which programs receive resources, expected data milestones, and a credible runway through those milestones.
• Keep FHTX on a catalyst watchlist rather than shorting immediately after the drawdown. Revisit a defined-risk bearish position only if cash guidance deteriorates, another program is deprioritized, or financing becomes necessary; a partnership or convincing clinical signal invalidates that setup.
• No actionable read-through to CFG or EVR from this item. For LLY, treat the impact as immaterial absent evidence that the terminated collaboration had meaningful economics or changes Lilly’s broader development plans.